company background image
PAB logo

Patrys CHIA:PAB Stock Report

Last Price


Market Cap







14 Jun, 2024


Company Financials

PAB Stock Overview

Develops and commercializes antibody technologies for the treatment of cancer in Australia.

PAB fundamental analysis
Snowflake Score
Future Growth0/6
Past Performance0/6
Financial Health6/6

Patrys Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Patrys
Historical stock prices
Current Share PriceAU$0.007
52 Week HighAU$0.012
52 Week LowAU$0.006
1 Month Change-6.67%
3 Month Change-22.22%
1 Year Change-33.33%
3 Year Change-85.42%
5 Year Change-72.00%
Change since IPO-80.55%

Recent News & Updates

Recent updates

Shareholder Returns

PABAU BiotechsAU Market

Return vs Industry: PAB underperformed the Australian Biotechs industry which returned 4.1% over the past year.

Return vs Market: PAB underperformed the Australian Market which returned 8.6% over the past year.

Price Volatility

Is PAB's price volatile compared to industry and market?
PAB volatility
PAB Average Weekly Movement16.0%
Biotechs Industry Average Movement11.0%
Market Average Movement8.7%
10% most volatile stocks in AU Market16.4%
10% least volatile stocks in AU Market3.2%

Stable Share Price: PAB's share price has been volatile over the past 3 months.

Volatility Over Time: PAB's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of Australian stocks.

About the Company


Patrys Limited, together with its subsidiaries, develops and commercializes antibody technologies for the treatment of cancer in Australia. Its lead technology is Deoxymab 3E10, a DNA damage-repair antibody that penetrates cell nuclei. The company focuses on developing PAT-DX1, an antibody fragment for the treatment of primary and secondary brain cancer.

Patrys Limited Fundamentals Summary

How do Patrys's earnings and revenue compare to its market cap?
PAB fundamental statistics
Market capAU$14.39m
Earnings (TTM)-AU$5.12m
Revenue (TTM)AU$1.70m


P/S Ratio


P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PAB income statement (TTM)
Cost of RevenueAU$0
Gross ProfitAU$1.70m
Other ExpensesAU$6.82m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date


Earnings per share (EPS)-0.0025
Gross Margin100.00%
Net Profit Margin-302.26%
Debt/Equity Ratio0%

How did PAB perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.